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Abstract
Background: Beta‐galactosidase‐1 (GLB1) is a lysosomal hydrolase that is
responsible for breaking down specific glycoconjugates, particularly GM1
(monosialotetrahexosylganglioside). Pathogenic variants in GLB1 cause two dif-
ferent lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharido-
sis type IVB. In GM1 gangliosidosis, decreased β‐galactosidase‐1 enzymatic
activity leads to the accumulation of GM1 gangliosides, predominantly within the
CNS. We present a 22‐month‐old proband with GM1 gangliosidosis type II (late‐
infantile form) in whom a novel homozygous in‐frame deletion
(c.1468_1470delAAC, p.Asn490del) in GLB1 was detected.
Methods: We used an experimental protein structure of β‐galactosidase‐1 to gen-
erate a model of the p.Asn490del mutant and performed molecular dynamic simu-
lations to determine whether this mutation leads to altered ligand positioning
compared to the wild‐type protein. In addition, residual mutant enzyme activity in
patient leukocytes was evaluated using a fluorometric assay.
Results: Molecular dynamics simulations showed the deletion to alter the cat-
alytic site leading to misalignment of the catalytic residues and loss of collective
motion within the model. We predict this misalignment will lead to impaired
catalysis of β‐galactosidase‐1 substrates. Enzyme assays confirmed diminished
GLB1 enzymatic activity (~3% of normal activity) in the proband.
Conclusions: We have described a novel, pathogenic in‐frame deletion of GLB1
in a patient with GM1 gangliosidosis type II.
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1 | INTRODUCTION
GLB1 (MIM: 611458) is located on chromosome 3 and
gives rise to two alternatively spliced mRNA transcripts that
encode beta‐galactosidase‐1 (GLB1) and the elastin‐binding†Authors contributed equally.
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protein (EBP) (Privitera, Prody, Callahan, & Hinek, 1998).
β‐galactosidase‐1 is a lysosomal hydrolase responsible for
cleaving terminal beta‐galactose residues from ganglioside
substrates and other glycoconjugates (Yoshida et al., 1991).
Pathogenic alterations in GLB1 lead to a reduction in affin-
ity for at least one substrate, resulting in either the toxic
accumulation of GM1 ganglioside in the nervous system
leading to progressive neurological deterioration (GM1 gan-
gliosidosis) or defective storage of galactosyl oligosaccha-
rides and keratin sulfate causing mucopolysaccharidosis
type IVB, Morquio type (MIM: 253010) (Regier & Tifft,
1993). In GM1 gangliosidosis, defective β‐galactosidase‐1
causes cell lysosomes to accumulate GM1 ganglioside and
other glycoconjugates over time—a process that has the
most pronounced effects on the central nervous system
(CNS) since gangliosides are particularly abundant in the
neuronal plasma membrane (Posse de Chaves & Sipione,
2010). This accumulation leads to neuronal cell death and
progressive CNS dysfunction with variable severity and age
at onset (Brunetti‐Pierri & Scaglia, 2008).
GM1 gangliosidosis is divided into three types that gen-
erally correlate with residual enzyme activity, of which
type I (MIM: 230500) is the most severe and has the earli-
est onset (Regier and Tifft, 1993). Type I symptoms appear
before 1 year of age and present with CNS dysfunction,
psychomotor regression, “coarse” facial features, cardiac
involvement, skeletal abnormality, macular cherry‐red
spots, and hepatosplenomegaly (Caciotti et al., 2011). Type
II (MIM: 230600) symptoms can appear between 7 months
and 3 years of age (late infantile) or 3–10 years of age (ju-
venile), and include progressive motor abnormalities, mus-
cle weakness, seizures, strabismus, corneal clouding, and
diffuse brain atrophy (Caciotti et al., 2011; Regier and
Tifft, 1993). Cardiac involvement, skeletal abnormalities,
and hepatosplenomegaly can also be seen, though typically
not to the extent seen in type I (Caciotti et al., 2011). Type
III (MIM: 230650) usually presents between 3 to 30 years
of age with slurred speech, dystonia, parkinsonism, cerebel-
lar dysfunction, and mild vertebral deformity and is the
mildest form (Caciotti et al., 2011). In practice, distinguish-
ing between type I and II GM1 gangliosidosis can be chal-
lenging given their overlapping clinical presentation and
age of onset, a difficulty not encountered with type III
cases (Regier & Tifft, 1993). Features that can be used to
distinguish between type I and II GM1 gangliosidosis
include the presence of cherry‐red macula and placental
storage of GM1 ganglioside in type I cases (Roberts,
Ampola, & Lage, 1991).
In this report, we describe a patient presenting with phe-
notypes most consistent with a diagnosis of GM1 gan-
gliosidosis type II. Sequencing revealed the presence of a
novel homozygous in‐frame deletion in GLB1. We per-
formed detailed structural modeling and molecular dynamic
simulations to determine the impact of this variant on
GLB1 protein function. In addition, an enzyme assay
showed reduced β‐galactosidase‐1 activity, thus supporting
our structural analyses.
2 | CLINICAL DESCRIPTION
The proband initially presented at 22 months old with the
tentative diagnosis of Hurler syndrome (mucopolysacchari-
dosis Ih, MIM: 607014). Her constellation of symptoms
first began to appear upon her premature delivery at
26 weeks of gestation. At birth, the proband had retinopa-
thy of prematurity leading to blindness, apnea, congenital
gastroschisis, gastroesophageal reflux disease, oral aver-
sion, a left ovarian cyst, a ventricular septal defect (VSD),
patent ductus arteriosus (PDA), and dysphagia. Subse-
quently, she developed bronchopulmonary dysplasia due to
respirator use and later on experienced an intraventricular
hemorrhage with sequela of tonic–clonic seizures. Several
corrective surgeries were performed including a gastroschi-
sis closure, Nissen fundoplication, gastrostomy for oral
aversion and dysphagia, left laparoscopic oophorectomy,
PDA ligation, and VSD repair.
Before her arrival at our clinic, brain MRI and spinal
X‐ray had been performed. The brain MRI revealed
encephalomalacia of the inferior cerebellar hemispheres
consistent with the proband's intraventricular hemorrhage,
borderline inadequate myelination patterns, and bilateral
mastoid effusions. The spinal X‐rays showed gibbus defor-
mity with thoracolumbar kyphosis and scoliosis and AP
foreshortening with inferior anterior beaking at L2‐L5.
When the proband was first seen by genetics, she displayed
failure to thrive, motor regression, and stiffening of joints
in addition to the symptoms noted above. Her physical
examination was notable for abnormally flat facial profile,
small mouth and prominent tongue, gingival hyperplasia,
hepatomegaly, generalized hypotonia, shortened limbs, and
nonambulatory gait requiring bilateral ankle‐foot orthotic
braces. A lysosomal enzyme panel was performed for clini-
cal suspicion of Hurler syndrome.
While alpha‐L‐iduronidase activity was normal, the proband
was found to have 3% of normal beta‐galactosidase‐1 activity.
Subsequent GLB1 sequencing revealed that the proband had a
homozygous deletion in GLB1, denoted c.1468_1470delAAC
[Chr3(GRCh37): g.33058210_33058212del, NM_000404.3:
c.1468_1470del, NP_000395.2: p.Asn490del]. This alteration
has been observed rarely in gnomAD (rs780232995, allele
count: 2/277218, MAF: 0.000007215%; Latino population
allele count: 2/34420, MAF: 0.00005811%) (Lek et al., 2016).
A clinical microarray (Affymetrix CytoScan HD) confirmed
that there were no other deletions, duplications, or copy num-
ber variations of clinical significance. Additionally, no long
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contiguous stretches of homozygosity were reported by
microarray. The mechanism whereby p.Asn490del impacts
GLB1 enzymatic function is unknown. Other similar in‐frame
deletions in GLB1 have been reported; however, they fall in
other regions of the protein (Caciotti et al., 2011; Santamaria,
Blanco, Chabás, Grinberg, & Vilageliu, 2007; Yang, Wu, &
Tsai, 2010). In order to determine the effects of this mutation,
we performed molecular dynamics simulations comparing the
mutant and wild‐type (WT) protein.
Following genetic testing, an osseous survey detected
multiple abnormalities in the proband consistent with
dysostosis multiplex (Figure 1). The proband was ulti-
mately diagnosed with GM1 gangliosidosis type II, though
her presenting hepatomegaly, coarse facial features, and
gingival hyperplasia are more typical of type I. It should
be noted that the types of GM1 gangliosidosis overlap in
their phenotypic spectrum. Her enzyme assay detected
~3% (0.49 nmol/hr/mg, normal range 13.5‐176) β‐galacto-
sidase activity which falls in the range expected for late‐
infantile type II patients at 1%–5% of normal activity.
Type I GM1 gangliosidosis typically exhibit negligible
levels of β‐galactosidase activity (Suzuki et al., 2014).
Continued multispecialty follow‐ups were recommended in
order to monitor the disease's progression and treat the
proband's symptoms.
3 | METHODS
We used the experimental structure of GLB1 (PDB ID
3thc) (Ohto et al., 2012) in molecular modeling. Loops that
were unresolved in the experimental structure were added
(Eswar et al., 2006) and a model of p.Asn490del was gen-
erated. We used implicit solvent molecular dynamics (Gen-
eralized Bourne with Simple Switching (Chocholousova &
Feig, 2006; Feig et al., 2004) as implemented in (Discovery
Studio Modeling Environment, Release 2017, San Diego:
Dassault Systèmes, 2016), the CHARMM36 force field, an
interaction cutoff of 12Å, with strength tapering beginning
at 10Å, a simulation time step of 1 fs, and conformations
recorded every 2 ps. To focus our simulations on the
ligand‐binding site and catalytic residues, large interdomain
motions were restrained using harmonic constraints. GLB1
was simulated with bound beta‐D‐galactose as described in
the ZINC database (Irwin & Shoichet, 2005) (ID 2597049).
Each initial conformation was used to generate 5 replicates.
Each replicate was independently energy minimized for
2,000 steps by steepest descent, minimized for 2,000 steps
by conjugate gradient, heated to 300K over 300 ps via a
Langevin thermostat, and simulated for 12 ns. One replicate
of each sequence was extended for an additional 10 ns and
without constraints. We used VMD for molecular visualiza-
tion (Humphrey, Dalke, & Schulten, 1996).
4 | RESULTS
Asn490 is located within a ligand‐binding loop and the
nearby Tyr485 makes a hydrogen bond with the ligand
(Figure 2). In our simulations, the loop containing Tyr485
moved away from the ligand. In unconstrained simulations
of WT GLB1, the most significant motions were coordi-
nated interdomain motions. In unconstrained simulations of
p.Asn490del, we observed the same type of interdomain
motions, but their magnitude was diminished and less coor-
dinated. Additionally, the motion of the catalytic loop was
significantly greater than was observed in WT. Collective
protein motions are typically related to function, which
have been validated through functional‐structural studies in
the literature (Caulfield & Medina‐Franco, 2011; Caulfield
et al., 2014; Fiesel et al., 2015; Kayode et al., 2016; Pusch-
mann et al., 2017; Zhang et al., 2013). The loss of collec-
tive motion, as we have observed for p.Asn490del, is
likely to have a substantial impact on protein function.
Thus, our simulations indicate a potential mechanism for
the observed poor enzymatic activity—altered ligand inter-
actions and loss of coordinated motions.
5 | DISCUSSION
GM1 gangliosidosis is a rare disorder with an incidence of
approximately 1:100,000–1:200,000 live births. Because of
its rarity and the overlapping symptoms with the other neu-
rodegenerative disorders, GM1 gangliosidosis is likely
underdiagnosed (Brunetti‐Pierri & Scaglia, 2008). While it
is known that accumulation of GM1 ganglioside and other
glycoconjugates as a result of β‐galactosidase deficiency is
responsible for the disease phenotype, the exact pathome-
chanism is still not completely understood and is an active
area of research (Brunetti‐Pierri & Scaglia, 2008). Substrate
reduction treatment has been proposed to halt the progres-
sion of the disease for individuals who have residual levels
of β‐galactosidase activity. Iminosugar drugs have shown
potential in reducing the storage of glycosphingolipids in
Glb1‐deficient mice, resulting in improved survival (Elliot‐
Smith et al., 2008; Kasperzyk et al., 2004). The iminosugar
Miglustat, which has been approved for the treatment of
Gaucher disease type I, was found to reverse disease pro-
gression in juvenile/adult GM1 gangliosidosis (Deodato et
al., 2017). More recently, injections of adeno‐associated
viral vectors (AAV9, AAVrh8) encoding GLB1 have
shown success in increasing GLB1 activity, reducing symp-
toms, and extending lifespan in mice with GM1 gangliosi-
dosis (Deodato et al., 2014; Weismann et al., 2015). This
form of gene therapy has been extended to larger animal
models with promising results paving the way for future
clinical trials in humans (Gray‐Edwards et al., 2017).
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We determined that the proband's unusual clinical pre-
sentation was due in part to her premature birth. The
retinopathy of prematurity and bronchopulmonary dysplasia
seen in the proband are obvious consequences of incom-
plete development (Crump, Winkleby, Sundquist, & Sund-
quist, 2012). Oral aversion requiring gastrostomy has been
reported in infants having gastroschisis (Overcash et al.,
2014). Use of gastrostomy to combat dysphagia and pre-
vent aspiration resulting from GM1/GM2 gangliosidosis is
also a common practice (Jarnes Utz et al., 2017).
The proband's coarse facial features, dysostosis multi-
plex, spinal deformities, psychomotor regression, hep-
atomegaly, dysphagia, apnea, cardiac defects, and
generalized hypotonia are consistent with a diagnosis of
GM1 gangliosidosis (Caciotti et al., 2011). While it would
appear that her tonic–clonic seizures were precipitated by
intraventricular hemorrhage secondary to preterm birth, sei-
zures are also a common complication of GM1 gangliosi-
dosis. Her joint stiffness and short limbs likely stemmed
from her skeletal abnormalities, another complication of
GM1 gangliosidosis.
Based on the family history, it is likely that the pro-
band's parents are both carriers of the in‐frame deletion.
Uniparental disomy (UPD) and consanguinity were ruled
out by microarray. The proband has no other full siblings
and has five maternal and four paternal half siblings. Car-
rier status of the parents and children could not be deter-
mined as they were lost to follow‐up. The variant has been
reported in dbSNP (rs780232995) and gnomAD and has a
minor allele frequency (MAF) of 0.00005811% in the
Latino population (Lek et al., 2016). It is possible that this
variant is more common in Latino populations given the
ethnicity of both parents.
We used molecular modeling and dynamics simulations
to generate an atomic mechanism for how the p.Asn490del
might alter β‐galactosidase enzymatic activity. Predictions
of this model could be confirmed using spectroscopic tech-
niques. Also, there is the potential for molecular modeling
to inform the underlying mechanisms of other metabolic
conditions caused by pathogenic mutations in GLB1. Look-
ing ahead, studies to examine flexible modes with advance
modeling techniques coupled with experimental work to
tease out putative binding sites, mutagenic regions of inter-
est, countermutations, and protein stabilities would benefit
the basic science and help accelerate drug discovery for
this target, which has been successful previously (Li,
FIGURE 1 Osseous survey of the
proband taken at 22 months of age showing
dysostosis multiplex. (a) Thoracolumbar
gibbus deformity, mild AP foreshortening
with inferior anterior beaking at L2‐L5 (L3
is the least affected). (a–c) Abnormal
hypoplastic vertebral bodies with
foreshortening and rounded appearance of
the endplates at T11, T12, and L1, and to a
lesser extent at T10. (b‐c) The medullary
cavity of the proximal humeral diaphysis
bilaterally appears expanded with relatively
thin cortices
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Caulfield, Qiu, Copland, & Tun, 2012; López‐Vallejo et
al., 2011; Puschmann et al., 2017; Zhang et al., 2013,
2014). These additional variants could be simulated to pre-
dict altered conformations and computational docking of
different ligands could be used to determine which ligands
are most strongly affected by each variant, thus aiding drug
design. We believe that molecular modeling fills an impor-
tant role in generating additional data and hypotheses for
functional studies—critical steps in the evaluation of
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FIGURE 2 Novel in‐frame deletion
affects ligand binding to GLB1. a) The
structure of GLB1 is shown with Asn490,
Tyr485, and ligand shown in detail. The
residues connecting Tyr485 to Asn490 are
highlighted and b) shown zoomed in. c)
After simulation, WT maintains the same
interaction between ligand and Tyr485,
while d) Asn490del showed altered
interaction. e) In unconstrained simulations,
we monitored the correlation between each
residue's motions and show these pairwise
correlations as a matrix. Certain regions of
the structure tend to move in a coordinated
way, corresponding to interdomain motions.
f) Asn490del shows the same type of
motion, but with less coordination. g) The
same correlation data are shown as a
density plot to emphasize the loss of strong
correlations
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